Literature DB >> 14610275

A dinucleotide motif in oligonucleotides shows potent immunomodulatory activity and overrides species-specific recognition observed with CpG motif.

Ekambar R Kandimalla1, Lakshmi Bhagat, Fu-Gang Zhu, Dong Yu, Yan-Ping Cong, Daqing Wang, Jimmy X Tang, Jin-Yan Tang, Cathrine F Knetter, Egil Lien, Sudhir Agrawal.   

Abstract

Bacterial and synthetic DNAs containing CpG dinucleotides in specific sequence contexts activate the vertebrate immune system through Toll-like receptor 9 (TLR9). In the present study, we used a synthetic nucleoside with a bicyclic heterobase [1-(2'-deoxy-beta-d-ribofuranosyl)-2-oxo-7-deaza-8-methyl-purine; R] to replace the C in CpG, resulting in an RpG dinucleotide. The RpG dinucleotide was incorporated in mouse- and human-specific motifs in oligodeoxynucleotides (oligos) and 3'-3-linked oligos, referred to as immunomers. Oligos containing the RpG motif induced cytokine secretion in mouse spleen-cell cultures. Immunomers containing RpG dinucleotides showed activity in transfected-HEK293 cells stably expressing mouse TLR9, suggesting direct involvement of TLR9 in the recognition of RpG motif. In J774 macrophages, RpG motifs activated NF-kappa B and mitogen-activated protein kinase pathways. Immunomers containing the RpG dinucleotide induced high levels of IL-12 and IFN-gamma, but lower IL-6 in time- and concentration-dependent fashion in mouse spleen-cell cultures costimulated with IL-2. Importantly, immunomers containing GTRGTT and GARGTT motifs were recognized to a similar extent by both mouse and human immune systems. Additionally, both mouse- and human-specific RpG immunomers potently stimulated proliferation of peripheral blood mononuclear cells obtained from diverse vertebrate species, including monkey, pig, horse, sheep, goat, rat, and chicken. An immunomer containing GTRGTT motif prevented conalbumin-induced and ragweed allergen-induced allergic inflammation in mice. We show that a synthetic bicyclic nucleotide is recognized in the C position of a CpG dinucleotide by immune cells from diverse vertebrate species without bias for flanking sequences, suggesting a divergent nucleotide motif recognition pattern of TLR9.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14610275      PMCID: PMC283587          DOI: 10.1073/pnas.2335947100

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  Immunostimulatory DNA for asthma: better than eating dirt.

Authors:  Eric S Silverman; Jeffrey M Drazen
Journal:  Am J Respir Cell Mol Biol       Date:  2003-06       Impact factor: 6.914

2.  Delineation of a CpG phosphorothioate oligodeoxynucleotide for activating primate immune responses in vitro and in vivo.

Authors:  G Hartmann; R D Weeratna; Z K Ballas; P Payette; S Blackwell; I Suparto; W L Rasmussen; M Waldschmidt; D Sajuthi; R H Purcell; H L Davis; A M Krieg
Journal:  J Immunol       Date:  2000-02-01       Impact factor: 5.422

3.  Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition.

Authors:  S Bauer; C J Kirschning; H Häcker; V Redecke; S Hausmann; S Akira; H Wagner; G B Lipford
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-24       Impact factor: 11.205

4.  Effect of chemical modifications of cytosine and guanine in a CpG-motif of oligonucleotides: structure-immunostimulatory activity relationships.

Authors:  E R Kandimalla; D Yu; Q Zhao; S Agrawal
Journal:  Bioorg Med Chem       Date:  2001-03       Impact factor: 3.641

5.  Immunostimulatory activity of CpG oligonucleotides containing non-ionic methylphosphonate linkages.

Authors:  D Yu; E R Kandimalla; Q Zhao; Y Cong; S Agrawal
Journal:  Bioorg Med Chem       Date:  2001-11       Impact factor: 3.641

6.  Modulation of immunostimulatory activity of CpG oligonucleotides by site-specific deletion of nucleobases.

Authors:  D Yu; E R Kandimalla; Q Zhao; Y Cong; S Agrawal
Journal:  Bioorg Med Chem Lett       Date:  2001-09-03       Impact factor: 2.823

Review 7.  Immunopharmacology of CpG DNA.

Authors:  Alexander Dalpke; Stefan Zimmermann; Klaus Heeg
Journal:  Biol Chem       Date:  2002-10       Impact factor: 3.915

8.  Divergent synthetic nucleotide motif recognition pattern: design and development of potent immunomodulatory oligodeoxyribonucleotide agents with distinct cytokine induction profiles.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Daqing Wang; Dong Yu; Fu-Gang Zhu; Jimmy Tang; Hui Wang; Ping Huang; Ruiwen Zhang; Sudhir Agrawal
Journal:  Nucleic Acids Res       Date:  2003-05-01       Impact factor: 16.971

9.  CpG penta- and hexadeoxyribonucleotides as potent immunomodulatory agents.

Authors:  Lakshmi Bhagat; Fu Gang Zhu; Dong Yu; Jimmy Tang; Hui Wang; Ekambar R Kandimalla; Ruiwen Zhang; Sudhir Agrawal
Journal:  Biochem Biophys Res Commun       Date:  2003-01-24       Impact factor: 3.575

10.  Requirement of nucleobase proximal to CpG dinucleotide for immunostimulatory activity of synthetic CpG DNA.

Authors:  Dong Yu; Ekambar R Kandimalla; Qiuyan Zhao; Lakshmi Bhagat; Yanping Cong; Sudhir Agrawal
Journal:  Bioorg Med Chem       Date:  2003-02-06       Impact factor: 3.641

View more
  15 in total

1.  Immunomodulatory oligonucleotides containing a cytosine-phosphate-2'-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists.

Authors:  Ekambar R Kandimalla; Lakshmi Bhagat; Yukui Li; Dong Yu; Daqing Wang; Yan-Ping Cong; Sam S Song; Jimmy X Tang; Tim Sullivan; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2005-04-28       Impact factor: 11.205

Review 2.  Immune modulatory oligonucleotides in the prevention and treatment of allergen-induced eustachian tube dysfunction in the animal model.

Authors:  Deidra A Blanks; Charles S Ebert
Journal:  Curr Allergy Asthma Rep       Date:  2008-11       Impact factor: 4.806

3.  Immune-Stimulatory Dinucleotide at the 5'-End of Oligodeoxynucleotides Is Critical for TLR9-Mediated Immune Responses.

Authors:  Mallikarjuna R Putta; Lakshmi Bhagat; Daqing Wang; Fu-Gang Zhu; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  ACS Med Chem Lett       Date:  2013-01-29       Impact factor: 4.345

4.  Novel drugs targeting Toll-like receptors for antiviral therapy.

Authors:  Mira C Patel; Kari Ann Shirey; Lioubov M Pletneva; Marina S Boukhvalova; Alfredo Garzino-Demo; Stefanie N Vogel; Jorge Cg Blanco
Journal:  Future Virol       Date:  2014-09       Impact factor: 1.831

5.  Immunomodulatory Agents with Antivascular Activity in the Treatment of Non-Small Cell Lung Cancer: Focus on TLR9 Agonists, IMiDs and NGR-TNF.

Authors:  Angelo Corti; Monica Giovannini; Carmen Belli; Eugenio Villa
Journal:  J Oncol       Date:  2010-06-03       Impact factor: 4.375

6.  Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.

Authors:  Sridhar Dharmapuri; Daniela Peruzzi; Carmela Mennuni; Francesco Calvaruso; Saverio Giampaoli; Gaetano Barbato; Ekambar R Kandimalla; Sudhir Agrawal; Elisa Scarselli; Giuseppe Mesiti; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2009-07-21       Impact factor: 11.454

7.  Impact of secondary structure of toll-like receptor 9 agonists on interferon alpha induction.

Authors:  Dong Yu; Mallikarjuna R Putta; Lakshmi Bhagat; Meiru Dai; Daqing Wang; Anthony F Trombino; Tim Sullivan; Ekambar R Kandimalla; Sudhir Agrawal
Journal:  Antimicrob Agents Chemother       Date:  2008-10-13       Impact factor: 5.191

8.  Stabilized immune modulatory RNA compounds as agonists of Toll-like receptors 7 and 8.

Authors:  Tao Lan; Ekambar R Kandimalla; Dong Yu; Lakshmi Bhagat; Yukui Li; Daqing Wang; Fugang Zhu; Jimmy X Tang; Mallikarjuna R Putta; YanPing Cong; Anthony F Trombino; Tim Sullivan; Sudhir Agrawal
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-14       Impact factor: 11.205

9.  TLR9 agonist acts by different mechanisms synergizing with bevacizumab in sensitive and cetuximab-resistant colon cancer xenografts.

Authors:  Vincenzo Damiano; Rosa Caputo; Sonia Garofalo; Roberto Bianco; Roberta Rosa; Gerardina Merola; Teresa Gelardi; Luigi Racioppi; Gabriella Fontanini; Sabino De Placido; Ekambar R Kandimalla; Sudhir Agrawal; Fortunato Ciardiello; Giampaolo Tortora
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-16       Impact factor: 11.205

10.  An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy.

Authors:  Huagang Zhang; Laibin Liu; Dong Yu; Ekambar R Kandimalla; Hui Bin Sun; Sudhir Agrawal; Chandan Guha
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.